Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ESIDRIX vs ATACAND HCT
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Thiazide diuretic that inhibits the sodium-chloride symporter in the distal convoluted tubule of the nephron, reducing sodium and chloride reabsorption, leading to increased diuresis and decreased extracellular volume.
ATACAND HCT is a combination of candesartan, an angiotensin II receptor blocker (ARB), and hydrochlorothiazide, a thiazide diuretic. Candesartan blocks the vasoconstrictor and aldosterone-secreting effects of angiotensin II by selectively antagonizing the AT1 receptor, leading to vasodilation and reduced blood pressure. Hydrochlorothiazide inhibits the sodium-chloride symporter in the distal convoluted tubule of the nephron, increasing sodium, chloride, and water excretion, thereby reducing plasma volume and blood pressure.
Hypertension,Edema associated with congestive heart failure, cirrhosis, or renal disease
Treatment of hypertension, for patients not adequately controlled on monotherapy.
25-50 mg orally once daily; may increase to 100 mg once daily or 50 mg twice daily for resistant edema.
One tablet orally once daily. Initial dose: 16 mg candesartan/12.5 mg hydrochlorothiazide. Titrate to maximum 32 mg candesartan/25 mg hydrochlorothiazide once daily.
Terminal elimination half-life is approximately 10-15 hours (mean 12 hours); clinical context: half-life prolonged in renal impairment, requiring dose adjustment.
Candesartan: ~9 hours (terminal). Hydrochlorothiazide: 6-15 hours (terminal, mean ~10 hours).
Not significantly metabolized; primarily excreted unchanged in urine.
Candesartan is primarily metabolized by hepatic O-deethylation via CYP2C9 to an inactive metabolite. Hydrochlorothiazide is not significantly metabolized and is excreted unchanged by the kidneys.
Renal: approximately 70% excreted unchanged in urine; biliary/fecal: less than 10%.
Candesartan: ~33% renal, ~67% biliary/fecal. Hydrochlorothiazide: >95% renal.
Approximately 75% bound to plasma proteins, primarily albumin.
Candesartan: >99% (primarily albumin). Hydrochlorothiazide: 40-70% (primarily albumin).
Vd is 0.1-0.2 L/kg; indicates limited extravascular distribution consistent with hydrophilic properties.
Candesartan: 0.13 L/kg (extensive tissue distribution). Hydrochlorothiazide: 0.83-2.5 L/kg (distributes into plasma and red blood cells).
Oral: bioavailability is approximately 80-90%.
Candesartan: ~15% (absolute, prodrug conversion). Hydrochlorothiazide: ~70% (oral).
GFR 25-50 m L/min: administer every 12 hours; GFR 10-25 m L/min: administer every 24 hours; GFR <10 m L/min: not recommended due to ineffectiveness.
Contraindicated if GFR <30 m L/min/1.73 m2. No adjustment for GFR 30-50 m L/min/1.73 m2. Use with caution and monitor renal function.
Child-Pugh Class B or C: reduce dose by 50% or use with caution due to risk of electrolyte disturbances and hepatic encephalopathy.
Mild to moderate hepatic impairment (Child-Pugh A or B): No dose adjustment. Severe impairment (Child-Pugh C): Not recommended due to hydrochlorothiazide accumulation risk.
1-2 mg/kg orally once daily; maximum 50 mg/day.
Safety and efficacy not established in pediatric patients (<18 years).
Start at 12.5-25 mg orally once daily; monitor electrolytes and renal function; adjust dose based on response and tolerability.
No initial dose adjustment required. Use caution due to increased sensitivity to hypotension and electrolyte disturbances; monitor renal function and electrolytes.
Not applicable
None.
Hypokalemia,Hyperuricemia,Hypomagnesemia,Hypercalcemia,Orthostatic hypotension,Photosensitivity,Systemic lupus erythematosus exacerbation,Sulfonamide allergy cross-sensitivity
Fetal toxicity: Use in pregnancy can cause oligohydramnios, fetal renal dysfunction, and skull ossification defects. Discontinue as soon as possible when pregnancy is detected.,Hypotension: Symptomatic hypotension may occur in volume-depleted patients. Correct volume depletion before initiation.,Impaired renal function: Monitor renal function due to risk of acute renal failure, especially in patients with renal artery stenosis.,Electrolyte imbalances: Hydrochlorothiazide can cause hypokalemia, hyponatremia, hypomagnesemia, and hypercalcemia; candesartan can cause hyperkalemia.,Metabolic effects: Thiazides may increase serum cholesterol, triglycerides, and uric acid levels; may cause hyperglycemia.,Acute angle-closure glaucoma: Hydrochlorothiazide can cause acute transient myopia and acute angle-closure glaucoma.,Systemic lupus erythematosus: Thiazides have been reported to cause exacerbation or activation of SLE.,Non-melanoma skin cancer: Thiazide diuretics may increase risk; monitor for skin lesions.
Anuria,Hypersensitivity to hydrochlorothiazide or sulfonamide-derived drugs
Hypersensitivity to candesartan, hydrochlorothiazide, or any component of the formulation.,Anuria (hydrochlorothiazide component).,Pregnancy (second and third trimesters).,Severe renal impairment (Cr Cl <30 m L/min).,Concomitant use with aliskiren in patients with diabetes mellitus.
Avoid high-sodium foods as they reduce antihypertensive efficacy. Limit potassium-rich foods (bananas, oranges) only if directed; hypokalemia risk is counteracted by high intake. Grapefruit juice may decrease HCTZ absorption; separate intake by 4 hours. Reduce alcohol intake to prevent additive hypotension.
Avoid salt substitutes containing potassium chloride unless approved by your doctor. Limit high-potassium foods (e.g., bananas, oranges, tomatoes) if hyperkalemia risk is present. Take hydrochlorothiazide with food or milk to reduce gastrointestinal upset. Grapefruit juice has no significant interaction with this combination.
First trimester: Limited human data; potential for fetal bradycardia and hypotension. Second and third trimesters: Increased risk of fetal hypotension, renal dysfunction, oligohydramnios, and skull ossification delays.
Pregnancy Category D. First trimester: potential fetotoxicity; second and third trimesters: ACE inhibitor exposure causes oligohydramnios, fetal renal dysfunction, skull ossification defects, and neonatal renal failure. Angiotensin receptor blocker (ARB) component: similar adverse effects. Thiazide diuretic: risk of fetal/neonatal jaundice, thrombocytopenia, and electrolyte disturbances. Use contraindicated in pregnancy.
Excreted in human milk; M/P ratio unknown. Due to potential for adverse effects (e.g., electrolyte disturbances), caution advised; avoid if possible, especially in preterm infants.
Candesartan (ARB) and hydrochlorothiazide (HCTZ) are excreted in breast milk. M/P ratio not established for candesartan; HCTZ M/P ratio is approximately 0.6. HCTZ may suppress lactation. Use not recommended during breastfeeding due to potential adverse effects in the infant, including electrolyte imbalance, hypotension, and renal impairment.
No routine dose adjustment recommended based on pharmacokinetic changes; however, use lowest effective dose due to altered volume of distribution and clearance.
Dose adjustments not applicable; drug is contraindicated in pregnancy. If unintentionally exposed, discontinue as soon as pregnancy is detected. No dose adjustment recommendations for pregnancy due to lack of safe use data.
Hydrochlorothiazide (HCTZ) in Esidrix may unmask diabetes (hyperglycemia), exacerbate gout (hyperuricemia), and cause hypokalemia (especially at high doses). Monitor electrolytes and renal function. Sunset yellow dye in tablets may cause allergic reactions in aspirin-sensitive patients.
ATACAND HCT is a fixed-dose combination of candesartan (an angiotensin II receptor blocker) and hydrochlorothiazide (a thiazide diuretic). Monitor renal function and electrolytes, especially potassium and sodium, within 2 weeks of initiation and periodically thereafter. Avoid use in pregnancy; discontinue as soon as pregnancy is detected. May cause symptomatic hypotension, particularly in volume-depleted patients; correct volume depletion before starting. Can exacerbate gout due to thiazide-induced hyperuricemia. Not recommended for use with aliskiren in patients with diabetes or renal impairment (GFR <60 m L/min).
Take in the morning to avoid nocturia.,Avoid prolonged sun exposure; use sunscreen as photosensitivity may occur.,Report signs of electrolyte imbalance: muscle cramps, weakness, irregular heartbeat.,May increase blood sugar; monitor if diabetic.,Do not take with alcohol or other blood pressure medications without consulting doctor.
Do not take if you are pregnant, plan to become pregnant, or are breastfeeding.,Take exactly as prescribed; do not skip doses or double up.,Drink adequate fluids to prevent dehydration unless instructed otherwise by your doctor.,Avoid alcohol and NSAIDs (e.g., ibuprofen) as they may increase side effects.,Report symptoms like lightheadedness, excessive thirst, muscle cramps, or irregular heartbeat.,Monitor blood pressure regularly at home and keep a log.,This medication may increase sensitivity to sunlight; use sunscreen and protective clothing.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ESIDRIX vs ATACAND HCT, answered by our medical review team.
ESIDRIX is a Thiazide Diuretic that works by Thiazide diuretic that inhibits the sodium-chloride symporter in the distal convoluted tubule of the nephron, reducing sodium and chloride reabsorption, leading to increased diuresis and decreased extracellular volume.. ATACAND HCT is a Angiotensin II Receptor Blocker / Thiazide Diuretic that works by ATACAND HCT is a combination of candesartan, an angiotensin II receptor blocker (ARB), and hydrochlorothiazide, a thiazide diuretic. Candesartan blocks the vasoconstrictor and aldosterone-secreting effects of angiotensin II by selectively antagonizing the AT1 receptor, leading to vasodilation and reduced blood pressure. Hydrochlorothiazide inhibits the sodium-chloride symporter in the distal convoluted tubule of the nephron, increasing sodium, chloride, and water excretion, thereby reducing plasma volume and blood pressure.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ESIDRIX and ATACAND HCT depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ESIDRIX is: 25-50 mg orally once daily; may increase to 100 mg once daily or 50 mg twice daily for resistant edema.. The standard adult dose of ATACAND HCT is: One tablet orally once daily. Initial dose: 16 mg candesartan/12.5 mg hydrochlorothiazide. Titrate to maximum 32 mg candesartan/25 mg hydrochlorothiazide once daily.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ESIDRIX and ATACAND HCT in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ESIDRIX is classified as Category C. First trimester: Limited human data; potential for fetal bradycardia and hypotension. Second and third trimesters: Increased risk of fetal hypotension, renal dysfunction, oligohydr. ATACAND HCT is classified as Category C. Pregnancy Category D. First trimester: potential fetotoxicity; second and third trimesters: ACE inhibitor exposure causes oligohydramnios, fetal renal dysfunction, skull ossificati. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.